HC Wainwright reiterated their hold rating on shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) in a research report sent to investors on Tuesday morning. HC Wainwright currently has a $0.50 price objective on the biopharmaceutical company’s stock.
SNSS has been the subject of a number of other research reports. Zacks Investment Research lowered Sunesis Pharmaceuticals from a strong-buy rating to a hold rating in a research report on Thursday, January 10th. ValuEngine lowered Sunesis Pharmaceuticals from a hold rating to a sell rating in a research report on Saturday, December 15th. Finally, Oppenheimer set a $6.00 price target on Sunesis Pharmaceuticals and gave the company a buy rating in a research report on Friday, March 8th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Sunesis Pharmaceuticals currently has an average rating of Hold and an average price target of $2.33.
NASDAQ:SNSS opened at $0.87 on Tuesday. Sunesis Pharmaceuticals has a 1-year low of $0.20 and a 1-year high of $3.78. The firm has a market capitalization of $26.57 million, a P/E ratio of -1.16 and a beta of 2.43.
A hedge fund recently bought a new stake in Sunesis Pharmaceuticals stock. Aisling Capital Management LP purchased a new stake in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,600,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,092,000. Sunesis Pharmaceuticals accounts for approximately 1.2% of Aisling Capital Management LP’s investment portfolio, making the stock its 12th biggest position. Aisling Capital Management LP owned 6.95% of Sunesis Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 41.23% of the company’s stock.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Read More: Investing in Dividend Stocks
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.